Skip to content
    Nextech logo

    Nextech

    Zurich, SwitzerlandFounded 1998
    www.nextechinvest.comLinkedIn
    Biotech & Life SciencesHealthcare

    Nextech Invest is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. Founded in 1998, it invests almost exclusively in oncology and oncology-adjacent therapeutics, diagnostics, and medical devices, from company inception through crossover rounds across the US and Europe.

    68% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-b (58% of deals). Average disclosed round size is $88.8M (across 38 rounds with reported amounts).

    Find people at Nextech on Goldilocks AI

    Portfolio

    38

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    3

    Team

    KP

    Kanishka Pothula

    Managing Partner

    RS

    Rocco Sgobbo

    Managing Partner, COO

    NB

    Niresh Berinpanathan

    Principal

    SS

    Sarah Soo-Hoo, MD

    Principal

    JK

    Jules Ketterlin

    Associate, Portfolio Management

    AJ

    Alessia Jaeggli

    Executive Assistant

    AN

    Amy Nelson

    Executive Assistant

    BC

    Brian Chen

    Finance & Operations Manager

    KK

    Kelsey Kalish

    Executive Assistant

    MW

    Marco Weibel

    Chief Financial Officer

    MP

    Meriel Peccolo

    Controller

    NL

    Nazira Landolt-Askarova

    Finance & Accounting Specialist

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    40 investments
    CompanyRoundAmountDate
    Stipple Bio logoStipple BioSeries A$100MApr 2026
    Atavistik Bio logoAtavistik BioSeries B$120MDec 2025
    Tubulis logoTubulisSeries C—Oct 2025
    Alpha-9 Oncology logoAlpha-9 OncologySeries C$175MOct 2024
    ProfoundBio logoProfoundBioSeries B$112MFeb 2024
    Mariana Oncology logoMariana OncologySeries B$175MSep 2023
    K36 Therapeutics logoK36 TherapeuticsSeries B$70MJun 2023
    Flare Therapeutics logoFlare TherapeuticsSeries B$123MMar 2023
    AAlpha-9 TheranosticsSeries B$75MDec 2022
    MOMA Therapeutics logoMOMA TherapeuticsSeries B$150MMay 2022
    TYRA Biosciences logoTYRA BiosciencesSeries B$106MMar 2021
    A2 Biotherapeutics logoA2 BiotherapeuticsSeries B$71.5MOct 2020
    A2 Biotherapeutics logoA2 BiotherapeuticsSeries B$71.5MOct 2020
    PMV Pharma logoPMV PharmaSeries D$70MAug 2020
    Kronos Bio logoKronos BioSeries A$105MJan 2020
    SSilverback TherapeuticsSeries B—Jan 2020
    Black Diamond Therapeutics, Inc logoBlack Diamond Therapeutics, IncSeries C$85MDec 2019
    Vividion Therapeutics logoVividion TherapeuticsSeries B$82MApr 2019
    PPeloton Therapeutics, Inc.Series E$150MFeb 2019
    Arrakis logoArrakisSeries B$75MJan 2019
    Arvinas logoArvinasSeries C$55MApr 2018
    Autolus Therapeutics plc logoAutolus Therapeutics plcUnknown$80MSep 2017
    Neon Therapeutics logoNeon TherapeuticsSeries B$36MJan 2017
    Cleave Biosciences logoCleave BiosciencesSeries B$37MAug 2016
    Jounce logoJounceUnknown$56MApr 2015
    Page 1 of 2

    Top Co-Investors

    Casdin Capital15 shared
    RA Capital Management11 shared
    Wellington Management9 shared
    Alexandria Venture Investments8 shared
    OrbiMed8 shared
    Cormorant Asset Management6 shared
    The Column Group5 shared
    Third Rock Ventures5 shared
    The Invus Group, LLC5 shared
    Canaan Partners5 shared
    GV5 shared
    Celgene5 shared
    Omega Funds5 shared
    Foresite Capital5 shared
    BVF Partners L.P.4 shared
    Samsara BioCapital4 shared
    Perceptive Advisors4 shared
    Redmile Group4 shared
    Surveyor Capital4 shared
    Euclidean Capital3 shared

    Last updated: 8 September 2026